Flutiform fluticasone/formoterol regulatory update

EMA's CHMP completed an arbitration procedure and recommended approval of an MAA for Flutiform fluticasone/formoterol to treat asthma. In October, SkyePharma said the decentralized review of the MAA from its partner Mundipharma would take longer than expected due to lack of complete consensus among the concerned member states at day 210 (see BioCentury, Oct. 24, 2011). ...